Astellas Pharma Inc.

4503

JP3942400007

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
1,506 ^JPY	+3.51%		+2.76%	-10.68%

Apr. 25	Astellas Pharma Inc. Announces Board and Committee Retirements	CI
Apr. 25	European Commission Approves Astellas Pharma Label Extension for Xtandi	MT

Astellas Pharma Inc : Astellas and UMN Announce Summary Results in Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374

January 15, 2014 at 01:48 am EST

MarketScreener.com By The editorial team

Astellas and UMN Announce Summary Results in Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374

Astellas Pharma Inc. (TSE: 4503; Headquaters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585

Latest news about Astellas Pharma Inc.

Astellas Pharma Inc. Announces Board and Committee Retirements	Apr. 25	CI
European Commission Approves Astellas Pharma Label Extension for Xtandi	Apr. 24	MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	Apr. 23	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	Apr. 22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22	CI
Lupin Launches Mirabegron Extended-Release Tablets in US	Apr. 21	MT
Japan Inc makes a renewed U.S. push as China fears mount	Apr. 17	RE
Middle East Tensions Blunt Asian Stock Markets Excepting China	Apr. 15	MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	Apr. 15	MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	Apr. 15	RE
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	Apr. 14	RE
Astellas Pharma Inc. Provides Impairment Loss for Intangible Assets Guidance for the Fourth Quarter 2023	Apr. 12	CI
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Apr. 12	CI
Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy	Apr. 03	MT
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy	Mar. 31	CI
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China	Mar. 28	MT
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Mar. 28	CI
Astellas Pharma Inc.'s Vyloy?? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer	Mar. 26	CI
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI? in Additional Recurrent Early Prostate Cancer Treatment Setting	Mar. 22	CI
Bayer to seek approval for menopausal relief drug after third trial win	Mar. 19	RE
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	Mar. 18	CI
Hewlett Packard Enterprise's HPE Asset Upcycling Services Selected by Astellas Pharma	Mar. 14	MT
China Approves Sale of Humanwell Healthcare Unit's Prostate Cancer Treatment	Mar. 06	MT
Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan	Mar. 03	CI
Transcript : Astellas Pharma Inc. - Special Call	Feb. 20

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q1 2024 Earnings Release (Projected)

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,455 JPY

Average target price

2,031 JPY

Spread / Average Target

+39.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTELLAS PHARMA INC.	-10.68%	16.77B
ELI LILLY AND COMPANY	+26.11%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.45%	354B
MERCK & CO., INC.	+20.45%	331B
ABBVIE INC.	+3.29%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.39%	144B

Other Pharmaceuticals